Literature DB >> 3053707

Selective inhibition of glycoprotein-processing enzymes. Differential inhibition of glucosidases I and II in cell culture.

G P Kaushal1, Y T Pan, J E Tropea, M Mitchell, P Liu, A D Elbein.   

Abstract

In this study, we compared the effects of 2,6-dideoxy-2,6-imino-7-O-(beta-D-glucopyranosyl)-D-glycero-L-gulohep titol (MDL) to those of the glucosidase I inhibitor, castanospermine, on the purified processing enzymes glucosidases I and II. WE also compared the effects of these two inhibitors on glycoprotein processing in cell culture using influenza virus-infected Madin-Darby canine kidney cells as a model system. With the purified processing enzymes, castanospermine was a better inhibitor of glucosidase I than of glucosidase II, whereas MDL is more effective against glucosidase II than glucosidase I. In cell culture at the appropriate dose, MDL also preferentially affected glucosidase II. Thus, at 250 micrograms/ml MDL, the major [3H]glucose-labeled (or [3H]mannose-labeled) glycopeptide from the viral hemagglutinin was susceptible to endoglucosaminidase H, and the oligosaccharide liberated by this treatment was characterized as a Glc2Man7-9GlcNAc on the basis of size, resistance to digestion by glucosidase I (but sensitivity to glucosidase II), methylation analysis, and Smith degradation studies. These data indicate that at appropriate concentrations of MDL (250 micrograms/ml), one can selectively inhibit glucosidase II in Madin-Darby canine kidney cells. However, at higher concentrations of inhibitor (500 micrograms/ml), both enzymes are apparently affected. Since MDL did not greatly inhibit the synthesis of lipid-linked saccharides or the synthesis of protein or RNA, it should be a useful tool for studies on the biosynthesis and role of N-linked oligosaccharides in glycoprotein function.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3053707

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Glucosidase inhibition enhances presentation of de-N-glycosylated hepatitis B virus epitopes by major histocompatibility complex class I in vitro and in woodchucks.

Authors:  Pamela A Norton; Stephan Menne; Gomathinayagam Sinnathamby; Lucy Betesh; Paul J Cote; Ramila Philip; Anand S Mehta; Bud C Tennant; Timothy M Block
Journal:  Hepatology       Date:  2010-10       Impact factor: 17.425

2.  Characterization and significance of delayed processing of the feline leukemia virus FeLV-FAIDS envelope glycoprotein.

Authors:  M L Poss; S L Quackenbush; J I Mullins; E A Hoover
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

Review 3.  Iminosugars: Promising therapeutics for influenza infection.

Authors:  Beatrice Ellen Tyrrell; Andrew Cameron Sayce; Kelly Lyn Warfield; Joanna Louise Miller; Nicole Zitzmann
Journal:  Crit Rev Microbiol       Date:  2016-12-08       Impact factor: 7.624

4.  Characterizing the selectivity of ER α-glucosidase inhibitors.

Authors:  Sarah O'Keefe; Quentin P Roebuck; Izumi Nakagome; Shuichi Hirono; Atsushi Kato; Robert Nash; Stephen High
Journal:  Glycobiology       Date:  2019-07-01       Impact factor: 4.313

5.  Development of a novel anti-hepatitis B virus agent via Sp1.

Authors:  Michiyo Hayakawa; Hideaki Umeyama; Mitsuo Iwadate; Y-H Taguchi; Yoshihiko Yano; Takashi Honda; Saori Itami-Matsumoto; Ritsuzo Kozuka; Masaru Enomoto; Akihiro Tamori; Norifumi Kawada; Yoshiki Murakami
Journal:  Sci Rep       Date:  2020-01-08       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.